REG - Hikma Pharmaceutical - Result of AGM

Hikma PharmaceuticalsAnnouncement

28/04/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230428:nRSb9338Xa&default-theme=true

RNS Number : 9338X  Hikma Pharmaceuticals Plc  28 April 2023

 

Hikma Pharmaceuticals PLC

Results of 2023 Annual General Meeting

LONDON, 28 April 2023 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK)
(OTC: HKMPY) (LEI:549300BNS685UXH4JI75) announces its Annual General Meeting
("AGM"), held at Sofitel London St James, 6 Waterloo Place, London SW1Y 4AN
and virtually on 28 April 2023 commenced at 11 am. All the proposed
resolutions were duly passed by shareholders by way of a poll. Resolutions 1
to 20 were passed as ordinary resolutions and Resolutions and 21 to 24 were
passed as special resolutions.

Copies of the resolutions dealing with special business passed at the AGM have
been submitted to the FCA's Electronic Submission System and will be available
from the National Storage Mechanism.

The total number of votes cast on the poll for each resolution (the full text
of the resolutions is detailed in the notice of the AGM dated 16 March 2023)
is set out below. The number of Ordinary Shares in issue on 27 April 2023 was
233,821,373.  There were 12,833,233 Ordinary Shares held in treasury, which
are not counted in the voting capital of the Company which, therefore, was
220,988,140.

 Resolution                                                                    Votes For    %       Votes Against  %     Total Cast   Withheld
 1. To receive the 2022 report and accounts                                    173,404,465  99.99   18,525         0.01  173,422,990  1,486,671
 2. To approve a final dividend of 37 cents per share                          174,904,572  100.00  3,407          0.00  174,907,979  1,682
 3. To re-appoint PricewaterhouseCoopers LLP as Auditor                        173,901,259  99.43   1,004,451      0.57  174,905,710  3,951
 4. To authorise the Audit Committee to determine the remuneration of the      174,902,468  100.00  4,247          0.00  174,906,715  2,946
 Auditor
 5. To elect Laura Balan as a Director of the Company                          174,560,635  99.80   345,653        0.20  174,906,288  3,373
 6. To elect Victoria Hull as a Director                                       172,985,379  98.90   1,920,959      1.10  174,906,338  3,322
 7. To elect Dr Deneen Vojta as a Director                                     174,145,610  99.57   759,059        0.43  174,904,669  4,992
 8. To re-elect Said Darwazah as a Director                                    167,417,879  95.79   7,363,833      4.21  174,781,712  127,949
 9. To re-elect Mazen Darwazah as a Director                                   166,197,026  95.09   8,584,687      4.91  174,781,713  127,948
 10. To re-elect Patrick Butler as a Director                                  169,789,166  97.08   5,115,966      2.92  174,905,132  4,529
 11.To re-elect Ali Al-Husry as a Director                                     173,667,423  99.36   1,114,623      0.64  174,782,046  127,615
 12. To re-elect John Castellani as a Director                                 174,135,021  99.56   770,111        0.44  174,905,132  4,529
 13. To re-elect Nina Henderson as a Director                                  172,945,073  98.88   1,961,390      1.12  174,906,463  3,198
 14. To re-elect Cynthia Flowers as a Director                                 174,560,963  99.80   345,325        0.20  174,906,288  3,373
 15. To re-elect Douglas Hurt as a Director                                    174,135,291  99.56   769,811        0.44  174,905,102  4,559
 16. To receive and approve the annual report on Remuneration                  169,944,824  97.16   4,959,681      2.84  174,904,505  5,145
 17. To approve the Directors' Remuneration Policy                             171,820,411  98.24   3,085,011      1.76  174,905,422  4,239
 18. To authorise the Directors to allot shares and grant rights to subscribe  169,738,766  97.05   5,168,220      2.95  174,906,986  2,674
 for shares
 19. To approve the Long-Term Incentive Plan 2023                              172,742,090  98.76   2,164,458      1.24  174,906,548  3,113
 20. To approve the Deferred Bonus Plan 2023                                   173,885,322  99.42   1,021,749      0.58  174,907,071  2,590
 21. To authorise the disapplication of pre-emption rights (General)           166,689,167  95.30   8,217,162      4.70  174,906,329  3,331
 22. To authorise the disapplication of pre-emption rights (Acquisition or     159,504,839  91.19   15,401,490     8.81  174,906,329  3,331
 Capital Investment)
 23. To authorise the Company to purchase Ordinary Shares                      173,797,944  99.42   1,018,079      0.58  174,816,023  93,638
 24. To authorise the Company to hold general meetings on not less than 14     169,319,647  96.81   5,588,186      3.19  174,907,833  1,828
 clear days' notice

 

 

Senior Independent Director

 

At the conclusion of the AGM, as reported in our 2022 Annual Report, Patrick
Butler stepped down as Senior Independent Director, Chair of the Nomination
and Governance Committee and as a member of the Audit Committee and
Remuneration Committee. Patrick Butler will remain on the Board as a
non-independent Non-Executive Director for one further year, stepping down no
later than the 2024 AGM. Victoria Hull was appointed as Senior Independent
Director and Chair of the Nomination and Governance Committee.

Declaration of final dividend

The dividend of 37 cents per share will be paid on 5 May 2023 to shareholders
on the register on 24 March 2023. Shareholders who are not resident in Jordan
have been given the option of receiving their dividend in Pounds Sterling. The
exchange rate in respect of this dividend will be $1.2532 to £1. The exchange
rate for Jordanian Dinar is fixed to the US Dollar at circa $1 to 0.71JD.

 

 

- ENDS -

Enquiries:

 

 Hikma Pharmaceuticals PLC
 Hussein Arkhagha                      +44 20 7399 2670

 Chief Counsel and Company Secretary

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEDFLAEDSEEL